HC Wainwright Estimates MeiraGTx’s Q3 Earnings (NASDAQ:MGTX)

MeiraGTx Holdings PLC (NASDAQ:MGTX) – HC Wainwright boosted their Q3 2026 earnings per share estimates for shares of MeiraGTx in a report released on Wednesday, July 8th. HC Wainwright analyst M. Kapoor now anticipates that the company will earn ($0.42) per share for the quarter, up from their previous estimate of ($0.45). HC Wainwright currently has a “Buy” rating and a $20.00 target price on the stock. The consensus estimate for MeiraGTx’s current full-year earnings is ($1.55) per share. HC Wainwright also issued estimates for MeiraGTx’s Q4 2026 earnings at ($0.42) EPS, FY2026 earnings at ($1.89) EPS, Q1 2027 earnings at ($0.44) EPS, Q2 2027 earnings at ($0.45) EPS and Q3 2027 earnings at ($0.47) EPS.

Several other brokerages have also weighed in on MGTX. Royal Bank Of Canada raised their price objective on shares of MeiraGTx from $25.00 to $26.00 and gave the stock an “outperform” rating in a report on Wednesday. Wall Street Zen raised MeiraGTx from a “sell” rating to a “hold” rating in a report on Sunday, April 5th. Chardan Capital reaffirmed a “buy” rating and set a $35.00 target price on shares of MeiraGTx in a report on Friday, March 27th. Weiss Ratings reiterated a “sell (d-)” rating on shares of MeiraGTx in a report on Tuesday, April 21st. Finally, Bank of America upped their price target on MeiraGTx from $14.00 to $16.00 and gave the company a “buy” rating in a research report on Friday, March 27th. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, MeiraGTx has a consensus rating of “Moderate Buy” and an average price target of $26.00.

MeiraGTx Price Performance

MGTX opened at $13.94 on Friday. MeiraGTx has a 12-month low of $6.62 and a 12-month high of $15.35. The stock has a market capitalization of $1.29 billion, a PE ratio of -9.42 and a beta of 1.20. The firm’s fifty day moving average price is $10.61 and its 200 day moving average price is $8.98.

MeiraGTx (NASDAQ:MGTX) last released its quarterly earnings results on Thursday, May 14th. The company reported ($0.57) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.61) by $0.04. The company had revenue of $0.29 million for the quarter, compared to analyst estimates of $17.00 million.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of MGTX. Perceptive Advisors LLC increased its stake in shares of MeiraGTx by 0.4% in the second quarter. Perceptive Advisors LLC now owns 12,626,103 shares of the company’s stock valued at $82,231,000 after purchasing an additional 45,000 shares during the period. Rubric Capital Management LP grew its holdings in MeiraGTx by 13.4% in the 1st quarter. Rubric Capital Management LP now owns 7,000,000 shares of the company’s stock worth $60,620,000 after buying an additional 824,669 shares in the last quarter. Adage Capital Partners GP L.L.C. grew its holdings in MeiraGTx by 7.1% in the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 6,034,578 shares of the company’s stock worth $39,345,000 after buying an additional 400,000 shares in the last quarter. Millennium Management LLC grew its holdings in MeiraGTx by 23.5% in the 4th quarter. Millennium Management LLC now owns 3,176,390 shares of the company’s stock worth $25,252,000 after buying an additional 604,121 shares in the last quarter. Finally, Erste Asset Management GmbH increased its position in MeiraGTx by 11.3% in the 4th quarter. Erste Asset Management GmbH now owns 789,702 shares of the company’s stock valued at $6,275,000 after acquiring an additional 80,000 shares during the period. Institutional investors own 67.48% of the company’s stock.

Insider Buying and Selling at MeiraGTx

In related news, insider Stuart Naylor sold 27,659 shares of the stock in a transaction dated Tuesday, July 7th. The shares were sold at an average price of $14.80, for a total value of $409,353.20. Following the sale, the insider owned 640,846 shares of the company’s stock, valued at $9,484,520.80. This trade represents a 4.14% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Alexandria Forbes sold 62,000 shares of MeiraGTx stock in a transaction dated Tuesday, May 19th. The shares were sold at an average price of $9.17, for a total transaction of $568,540.00. Following the completion of the sale, the chief executive officer owned 1,387,695 shares in the company, valued at approximately $12,725,163.15. This represents a 4.28% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 145,659 shares of company stock worth $1,550,213. 7.40% of the stock is owned by insiders.

Key Headlines Impacting MeiraGTx

Here are the key news stories impacting MeiraGTx this week:

• Positive Sentiment: HC Wainwright reiterated its Buy rating on MeiraGTx and maintained a $20 price target, implying meaningful upside from recent trading levels. MeiraGTx (NASDAQ:MGTX) Given “Buy” Rating at HC Wainwright
• Positive Sentiment: The firm raised earnings estimates across multiple future periods, including FY2026 EPS to -$1.89 from -$1.98 and FY2027 EPS to $0.83 from $0.67, signaling improving profitability expectations. Stuart Naylor Sells 27,659 Shares of MeiraGTx (NASDAQ:MGTX) Stock
• Neutral Sentiment: HC Wainwright also nudged up near-term quarterly EPS forecasts for Q3 2026, Q4 2026, Q1 2027, Q2 2027, and Q3 2027, reinforcing a constructive outlook but without changing the company’s still-loss-making profile in the near term.
• Neutral Sentiment: MeiraGTx shares had already jumped in the prior session on heavy volume, so some of the optimism may already be reflected in the stock. MeiraGTx (MGTX) Moves 5.5% Higher: Will This Strength Last?
• Negative Sentiment: Despite the upbeat revisions, the company is still expected to report negative earnings over the next several quarters, which can limit near-term enthusiasm.

MeiraGTx Company Profile

MeiraGTx Holdings plc is a clinical-stage biotechnology company dedicated to developing gene therapies for the treatment of rare diseases. Founded in 2014 as an outgrowth of research at University College London, the company focuses on leveraging adeno-associated virus (AAV) vectors to deliver functional genes to target tissues. MeiraGTx’s pipeline spans ocular, central nervous system and systemic indications, addressing conditions such as inherited retinal dystrophies and neurodegenerative disorders that currently lack effective therapies.

The company’s lead programs include AAV-based candidates designed to restore or replace defective genes underlying rare retinal diseases and to modulate cellular pathways in neurological disorders.